These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 23217267

  • 1. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.
    Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
    [Abstract] [Full Text] [Related]

  • 2. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [Abstract] [Full Text] [Related]

  • 5. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 8. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [Abstract] [Full Text] [Related]

  • 9. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 10. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
    Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W.
    Chin Med J (Engl); 2014 Dec; 127(2):208-12. PubMed ID: 24438605
    [Abstract] [Full Text] [Related]

  • 11. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 13. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J, IMPROVE Study Expert Panel.
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [Abstract] [Full Text] [Related]

  • 14. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 15. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E.
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Qureshi MS, Shaikh MZ.
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [Abstract] [Full Text] [Related]

  • 18. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 19. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).
    Shah S, Yang W, Hasan MI, Malek R, Molskov Bech O, Home P.
    Diabetes Technol Ther; 2013 Nov; 15(11):954-63. PubMed ID: 24053450
    [Abstract] [Full Text] [Related]

  • 20. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.